Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 22, 2022, titled "Zydus receives final approval and 180 days shared exclusivity from the USFDA for Selexipag Tablets".
Press Release Dec 22 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Selexipag Tablets, along with a period of shared exclusivity. The approval allows Zydus to market various strengths of Selexipag Tablets, which are used to treat pulmonary arterial hypertension. This approval marks a significant milestone as Zydus was among the first applicants to submit a complete application for these tablets. The drug is set to be manufactured at Zydus's facility in Ahmedabad, India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Dec 10 2022
- Press Release Dec 02 2022
- Press Release Dec 01 2022
- Press Release Nov 28 2022
- Press Release Nov 23 2022
Later from Zydus Lifesciences
- Loss of Share Certificates
- Press Release Dec 30 2022
- Press Release Jan 06 2023
- Press Release Jan 10 2023
- Zydus Lifesciences Limited Press Release Jan 12 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences